Edwards Lifesciences Corp
NYSE:EW
Edwards Lifesciences Corp
Net Income (Common)
Edwards Lifesciences Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
41%
|
CAGR 5-Years
32%
|
CAGR 10-Years
18%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$13.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
Edwards Lifesciences Corp
Glance View
Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.
See Also
What is Edwards Lifesciences Corp's Net Income (Common)?
Net Income (Common)
4.2B
USD
Based on the financial report for Dec 31, 2024, Edwards Lifesciences Corp's Net Income (Common) amounts to 4.2B USD.
What is Edwards Lifesciences Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
18%
Over the last year, the Net Income (Common) growth was 198%. The average annual Net Income (Common) growth rates for Edwards Lifesciences Corp have been 41% over the past three years , 32% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet